What were the results of the ENHERTU study?
Median overall survival
In a clinical study of 188 adults with previously treated HER2+ advanced stomach cancer, ENHERTU helped people live longer than with chemotherapy*
12.5
months
with ENHERTU
Half of the people taking
ENHERTU were alive at
12.5 months†
8.4
months
with chemotherapy
Half of the people taking
chemotherapy were alive at
8.4 months
Median overall survival is the length of time, from either the date of
diagnosis or the start of treatment, that half the people in a group are
still alive. A median is the middle number in a set of numbers.
Patients lived about 4 months longer with ENHERTU
*Chemotherapy used in the clinical study was the doctor’s choice between 2 commonly used chemotherapies (irinotecan or paclitaxel).
†63 (50%) of 126 people treated with ENHERTU were still alive after 12.5 months vs 23 (37%) of 62 people treated with chemotherapy.
Overall response rate
In the same clinical study, tumors shrank in more people treated with ENHERTU than with chemotherapy‡§
33% (41 of 126)
of people taking ENHERTU achieved a partial response, which means the tumor shrank by at least 30%
8% (10 of 126)
of people taking ENHERTU achieved a complete response, meaning their tumor could not be seen on imaging tests. This does not always mean the cancer has been cured
11% (7 of 62)
of people taking chemotherapy achieved a partial response, which means the tumor shrank by at least 30%
0% (0 of 62)
of people taking chemotherapy achieved a complete response
Overall response rate is the proportion of patients who have a partial or complete response to therapy.
Additional results
Disease control rate
84% (106 of 126) of people treated with ENHERTU vs 61% (38 of 62) of people treated with chemotherapy had their tumors respond to treatment in at least one of the following ways:
Shrink
or
Stop growing
or
Slow down
Disease control rate is the percentage of people who have achieved complete response, partial response, or stable disease. Stable
disease means tumors did not increase in size 20% or more or decrease in size 30% or more.
‡Chemotherapy used in the clinical trial was the doctor's choice between 2 commonly used chemotherapies (irinotecan or paclitaxel).
§Overall response rate was achieved by 51 out of 126 people with ENHERTU compared to 7 out of 62 people with chemotherapy.
||The response was observed by the treating doctor and then agreed upon by a review panel. A second scan 4 or more weeks after the first was used to confirm the results.
Starting treatment with ENHERTU?
Learn more about ENHERTU,
including Important Safety Information
HER2, human epidermal growth factor receptor 2.